S'abonner

Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes - 28/09/22

Doi : 10.1016/j.ajog.2022.05.056 
Jamie O. Lo, MD, MCR a, b, Jason C. Hedges, MD, PhD b, c, Guillermina Girardi, MSc, PhD d,
a Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR 
b Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 
c Department of Urology, Oregon Health & Science University, Portland, OR 
d Pregnancy and Perinatology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 

Corresponding author: Guillermina Girardi, MSc, PhD.

Abstract

Cannabis is the most commonly used federally illegal drug in the United States and the world, especially among people of reproductive age. In addition, the potency of cannabis products has increased significantly in the past decade. This is concerning because the available evidence suggests an adverse effect of cannabis exposure on male and female reproductive health. Exposure to cannabinoids may have differential impacts on female reproductive health across a woman’s lifespan, from preconception to pregnancy, throughout lactation, and during menopause. Moreover, cannabis use has been associated with adverse effects on fetal outcomes and longer-term offspring health and developmental trajectories. Despite the prevalence of cannabis use, there is limited available evidence regarding its safety, especially in regard to reproductive health, pregnancy, and lactation. The biological effects of cannabis are mediated by the endocannabinoid system, and studies have reported the presence of cannabinoid receptors in the male and female reproductive tract, on sperm and the placenta, suggesting that the endocannabinoid system plays a role in regulating reproduction. Cannabis use can affect male and female fertility and has been associated with altered reproductive hormones, menstrual cyclicity, and semen parameters. Use of cannabis in male patients has also been associated with erectile dysfunction, abnormal spermatogenesis, and testicular atrophy. In female patients, cannabis use has been associated with infertility and abnormal embryo implantation and development. The main psychoactive component of cannabis, the delta-9-tetrahydrocannabinol, can also cross the placenta and has been detected in breast milk. Maternal cannabis use during pregnancy and lactation has been associated with adverse effects, including small-for-gestational-age infants, preterm birth, fetal neurodevelopmental consequences, and impaired offspring sociobehavioral and cognitive development. The prevalence of cannabis use for alleviating menopausal symptoms has also increased despite the limited information on its benefits and safety. Given that cannabis use is on the rise, it is critical to understand its impact on reproductive health and offspring developmental outcomes. This is an understudied but timely subject requiring much further information to guide healthcare providers and those interested in conceiving or who are pregnant and lactating, and those at the end of their reproductive time span.

Le texte complet de cet article est disponible en PDF.

Key words : cannabinoids, cannabis, cannabis use disorder, delta-9-tetrahydrocannabinol, fertility, low birthweight, marijuana, maternal cannabis use, menopause, preterm birth, reproductive health, small for gestational age, substance use


Plan


 The authors report no conflict of interest.
 This study was supported by funding from the National Institutes of Health (grant number NIH P51-OD-011092).
 The contents of this article represent the authors’ views and do not constitute an official position of the National Institutes of Health or the US Government.
 All authors are responsible for the reported research, and all made substantial contributions to study conception, analysis, interpretation, manuscript drafting, and critical revision and approval of the final submitted version.


© 2022  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 227 - N° 4

P. 571-581 - octobre 2022 Retour au numéro
Article précédent Article précédent
  • Racism and perinatal health inequities research: where we have been and where we should go
  • Irene E. Headen, Michal A. Elovitz, Ashley N. Battarbee, Jamie O. Lo, Michelle P. Debbink
| Article suivant Article suivant
  • Maternal pregnancy outcomes in women with cardiomyopathy: a systematic review and meta-analysis
  • Elizabeth J. Eggleton, Kate J. McMurrugh, Catherine E. Aiken

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.